0.14
-0.015(-9.68%)
Currency In CAD
Address
505 8th Avenue S.W.
Calgary, AB T2P 1G2
Canada
Phone
403-770-2469
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
First IPO Date
July 13, 2021
| Name | Title | Pay | Year Born |
| J. Roderick Matheson | Executive Chairman & Chief Executive Officer | 150,000 | N/A |
| Harpreet Nijjar | Chief Financial Officer | 84,000 | 1988 |
| Mark Williams | President, Chief Science Officer & Director | 150,000 | 1972 |
| Jacqueline Groot | Corporate Secretary | 0 | N/A |
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
